US Stock Futures Signal Lower Start On Wall Street

Pre-open movers US stock futures dropped in early pre-market trade, ahead of economic data. The ISM non-manufacturing for October will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 48 points to 15,527.00, while the Standard & Poor's 500 index futures fell 5.20 points to 1,757.80. Futures for the Nasdaq 100 index dropped 10.50 points to 3,367.00. A Peek Into Global Markets European markets were lower today, with the Spanish Ibex Index declining 1.14%, London's FTSE 100 index dropping 0.59% and STOXX Europe 600 Index falling 0.30%. German DAX 30 index fell 0.42% and French CAC 40 Index declined 0.62%. UK retail sales increased 0.8% y/y in October. The European Commission lifted its growth forecast for the UK and lowered its economic growth view for the euro zone. Spanish jobless claims fell by 22,138 to 4.81 million in October. Asian markets ended mostly higher today. Japan's Nikkei Stock Average rose 0.17%, China's Shanghai Composite gained 0.35% and Hong Kong's Hang Seng Index declined 0.65%. Australia's ASX/S&P500 rose 0.77% and India's BSE Sensex tumbled 1.25%. Australia held its interest rate at 2.5%. Broker Recommendation Analysts at Deutsche Bank upgraded BlackBerry BBRY from “sell” to “hold.” The target price for BlackBerry is set to $6. BlackBerry's shares gained 1.92% to $6.62 in pre-market trading. Breaking news

• NYSE Euronext NYX reported a 21% increase in its Q3 net income. To read the full news, click here.
• Endo Health Solutions ENDP today announced that it has reached a definitive agreement to acquire Paladin Labs PLDLF, a leading Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion. To read the full news, click here.
• PS Business Parks PSB today announced the pricing of its public offering of 1,300,000 shares of its common stock at a price of $79.25 per share, resulting in gross proceeds of approximately $103.0 million before the underwriting discount and estimated offering expenses. To read the full news, click here.
• ImmunoGen IMGN announced today the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial's independent Data Monitoring Committee (DMC). To read the full news, click here.